Výsledky vyhledávání

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Report

Dr. Stein Sandven of NERSC on Arctic Regional Ocean Observing Systems

Autor: Sandven, Stein

Externí odkaz: https://hdl.handle.net/1956/2826

Safety and Tolerability of Dalcetrapib††Conflicts of interest: Dr. Stein has received grants for studies of lipid-modifying agents, has received consulting fees and honoraria for professional input regarding agents to modify lipid profile, and/or has delivered lectures for the American Association for Clinical Chemistry, Washington, District of Columbia; Abbott Laboratories, Abbott Park, Illinois; AstraZeneca, Wilmington, Delaware; the United States Food and Drug Administration, Washington, District of Columbia; F. Hoffmann-La Roche Ltd., Basel, Switzerland; Isis Pharmaceuticals, Inc., Carlsbad, California; Merck & Co., Whitehouse Station, New Jersey; the National Lipid Association, Jacksonville, Florida; Novartis International AG, Basel Switzerland; Reliant Pharmaceuticals, Inc., Liberty Corner, New Jersey; Daiichi Sankyo Co., Ltd., Tokyo, Japan; Schering-Plough Corporation, Kenilworth, New Jersey; Takeda Pharmaceutical Company Ltd., Osaka, Japan; and Wyeth, Madison, New Jersey. Dr. Stroes has received consulting fees and honoraria from F. Hoffmann-La Roche Ltd. and Novartis International AG. Dr. Steiner has received consulting fees and honoraria from F. Hoffmann-La Roche Ltd.; Solvay, Brussels, Belgium; Ethypharm S.A., Saint-Cloud, France; and Merck Frosst Canada Ltd. (Kirkland, Quebec, Canada)/Schering-Plough Corporation. Dr. Buckley has received research grants from AstraZeneca; Merck Sharp & Dohme, Dublin, Ireland; and Pfizer, Inc., New York, New York. Dr. Buckley has received honoraria and consulting fees and/or delivered lectures for AstraZeneca; Bristol-Myers Squibb, New York, New York; F. Hoffmann-La Roche Ltd.; Novartis International AG; Pfizer, Inc.; and Sanofi-Aventis, Paris, France. Dr. Capponi has received consulting fees and honoraria from F. Hoffmann-La Roche Ltd. Dr. Burgess is an employee of Hoffmann-La Roche Inc., Nutley, New Jersey. Drs. Niesor and Kallend are employees of F. Hoffmann-La Roche Ltd. Dr. Kastelein has received research grants, honoraria, or consulting fees for professional input and/or has delivered lectures for Pfizer, Inc.; Merck Sharp & Dohme; F. Hoffmann-La Roche Ltd.; Novartis International AG; Isis Pharmaceuticals, Inc.; Kowa Pharmaceutical Company Ltd., Nagoya, Japan; Schering-Plough Corporation; and AstraZeneca

Autor: Brendan M. Buckley, John J.P. Kastelein, Tracy Burgess, Erik S.G. Stroes, Evan A. Stein, David Kallend, Eric J. Niesor, George Steiner, Alessandro M. Capponi

Publikováno v: The American Journal of Cardiology. 104:82-91

Efficacy and safety data for dalcetrapib (RO4607381/JTT-705) are presented, following a report of increased mortality and cardiac events with another cholesteryl ester transfer protein inhibitor, torcetrapib, associated with off-target adverse effect

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e9edef2521a519b5f96be13dbd86ae73
https://doi.org/10.1016/j.amjcard.2009.02.061

Zobrazit plný text záznamu

Akademický článek

Frequency, Duration, and Predictors of Newly-Diagnosed Atrial Fibrillation Following Dual-Chamber Pacemaker Implantation in Patients Without a Previous History of Atrial Fibrillation ^† [†] Conflicts of interest: Dr. Mittal is a consultant for Biotronik and LifeWatch Corporation, Rosemont, Illinois; has received fellowship support from Boston Scientific Corporation, St. Paul, Minnesota, and Medtronic, Minneapolis, Minnesota; and has received speaking honoraria from Boston Scientific Corporation, Medtronic, and St. Jude Medical, St. Paul, Minnesota. Dr. Stein has received speaking honoraria from Boston Scientific Corporation, Medtronic, and St. Jude Medical and is a member of the advisory boards of Boston Scientific Corporation and Medtronic. Dr. Gilliam is a consultant for, has received speaking honoraria from, is a member of the advisory board of, and has received research funding from Boston Scientific Corporation. Stacia Merkel Kraus is a consultant for Boston Scientific Corporation. Drs. Meyer and Christman are employees of Boston Scientific Corporation.

Autor: Mittal, Suneet¹ smittal@chpnet.org, Stein, Kenneth², Gilliam, F. Roosevelt³, Kraus, Stacia Merkel⁴, Meyer, Timothy Edward⁵, Christman, Shelly Ann⁵

Publikováno v: American Journal of Cardiology. Aug2008, Vol. 102 Issue 4, p450-453. 4p.

Zobrazit plný text záznamu

OCD in Children and Adolescents: A Cognitive-Behavioral Treatment Manual - Dr. Stein is director of the MRC Research Unit on Anxiety and Stress Disorders in the Department of Psychiatry at the University of Stellenbosch in Cape Town, South Africa

Autor: Dan J. Stein

Publikováno v: CNS Spectrums. 3:85-86

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c5b6a00a5195957a57da4cf7d3cef902
https://doi.org/10.1017/s1092852900006556

Zobrazit plný text záznamu

Dr. Stein Replies

Autor: Michael D. Stein

Publikováno v: American Journal of Psychiatry. 161:929

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::40b4a375d9d57f6a428cd1f8e16fbb84
https://doi.org/10.1176/appi.ajp.161.5.929-a

Zobrazit plný text záznamu

Dr. Stein and Colleagues Reply

Autor: Murray B. Stein, Neal A. Kline, Jeffrey L. Matloff

Publikováno v: American Journal of Psychiatry. 160:1190-1190

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f8191a88a1fba78d5b01b71a3a92dd16
https://doi.org/10.1176/appi.ajp.160.6.1190

Zobrazit plný text záznamu

Tachyphylaxis and statin drugs∗∗Conflicts of Interest Disclosure: Dr. Stein receives research funding and is a consultant for Bristol-Myers Squibb, Kos, Merck, and Pfizer Pharmaceutical Companies. Dr. McBride receives research funding and is a consultant for Abbott, Bristol-Myers Squibb, Kos, Merck, Pfizer, and SmithKline Beecham Pharmaceuticals

Autor: James H. Stein, Patrick E. McBride

Publikováno v: The American Journal of Cardiology. 87:674

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::df768ee050e2877f1ee34e2d358f5a07
https://doi.org/10.1016/s0002-9149(01)01456-4

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání